Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction

The effect of the oral administration of a new vasodilator, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC-13013) on cerebral circulation in chronic cerebral infarction was studied by the 133Xenon inhalation method. Mean regional cerebral blood flow (rCBF) was increased in 6 out of 14 cases after 2 weeks of treatment. Hemispheric rCBF was significantly increased in both the affected and non-affected sides (10.8 and 13.4%, respectively) (p less than 0.05) without causing a change in blood pressure.